Systematic review of clinical trials assessing pharmacological properties of salvia species on memory, cognitive impairment and Alzheimer's disease

CNS Neuroscience and Therapeutics

Volumn 20, Issue 6, 2014, Pages 485-495

  Miroddi, Marco ^a   Navarra, Michele ^b   Quattropani, Maria C ^b   Calapai, Fabrizio ^a   Gangemi, Sebastiano ^a,c   Calapai, Gioacchino ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c CNR   (Italy)

Author keywords

Alzheimer's disease; Cognitive impairment; Memory; Salvia lavandulaefolia; Salvia officinalis

Indexed keywords

NOOTROPIC AGENT; PLACEBO; PLANT EXTRACT; SALVIA LAVANDULAEFOLIA EXTRACT; SALVIA OFFICINALIS EXTRACT; SUNFLOWER OIL; UNCLASSIFIED DRUG; PLANT MEDICINAL PRODUCT;

ALZHEIMER DISEASE; CHEMICAL COMPOSITION; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; MEMORY; PHYTOCHEMISTRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVIA; SALVIA LAVANDULAEFOLIA; SALVIA OFFICINALIS; SKIN ALLERGY; SYSTEMATIC REVIEW; TONIC CLONIC SEIZURE; CHEMISTRY; COGNITION DISORDERS; DRUG EFFECTS; PHYTOTHERAPY; PROCEDURES;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; HUMANS; MEMORY; PHYTOTHERAPY; PLANT PREPARATIONS; SALVIA;

EID: 84900550545     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12270     Document Type: Review

References (46)

1. Blumenthal M, Goldberg A, Brinckmann J. Herbal medicine: Expanded commission E monographs. Boston, MA: American Botanical Council, 2000.
2. Barnes J, Phillipson DJ. Sage. Herbal medicines, 3rd edn. London: The Pharmaceutical Press, 2007.
3. Clebsch B. The new book of salvias: Sages for every garden. Portland, OR: Timber Press, 2008.
4. Tildesley N, Kennedy D, Perry E, et al. Salvia lavandulaefolia (Spanish Sage) enhances memory in healthy young volunteers. Pharmacol Biochem Behav 2003;75:669-674.
5. DeFina PA, Moser RS, Glenn M, Lichtenstein JD, Fellus J. Alzheimer's disease clinical and research update for health care practitioners. J Aging Res 2013;2013:207178.
6. May BH, Lit M, Xue CC, et al. Herbal medicine for dementia: A systematic review. Phytother Res 2009;23:447-459.
7. Howes MJR, Perry NS, Houghton PJ. Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res 2003;17:1-18.
8. Perry NS, Bollen C, Perry EK, Ballard C. Salvia for dementia therapy: Review of pharmacological activity and pilot tolerability clinical trial. Pharmacol Biochem Behav 2003;75:651-659.
9. Scholey AB, Tildesley NT, Ballard CG, et al. An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers. Psychopharmacology 2008;198:127-139.
10. Imanshahidi M, Hosseinzadeh H. The pharmacological effects of Salvia species on the central nervous system. Phytother Res 2006;20:427-437.
11. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
12. Clark HD, Wells GA, Huët C, et al. Assessing the quality of randomized trials: Reliability of the Jadad scale. Control Clin Trials 1999;20:448-452.
13. Gagnier JJ, Boon H, Rochon P, et al. Reporting randomized, controlled trials of herbal interventions: An elaborated CONSORT statement. Ann Intern Med 2006;144:364-367.
14. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
15. Perry NB, Anderson RE, Brennan NJ, et al. Essential oils from dalmatian sage (Salvia officinalis L.): Variations among individuals, plant parts, seasons, and sites. J Agric Food Chem 1999;47:2048-2054.
16. Abu-Darwish M, Cabral C, Ferreira I, et al. Essential oil of common sage (Salvia officinalis L.) from Jordan: Assessment of safety in mammalian cells and its antifungal and anti-inflammatory potential. Biomed Res Int 2013;2013:538940.
17. Leung Albert Y, Foster S. Encyclopedia of common natural ingredients. New York: John Wiley & Sons Inc., 1996.
18. Tildesley N, Kennedy D, Perry E, et al. Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers. Physiol Behav 2005;83:699-709.
19. Zupkó I, Hohmann J, Rédei D, et al. Antioxidant activity of leaves of Salvia species in enzyme-dependent and enzyme-independent systems of lipid peroxidation and their phenolic constituents. Planta Med 2001;67:366-368.
20. Savelev S, Okello E, Perry N, Wilkins R, Perry E. Synergistic and antagonistic interactions of anticholinesterase terpenoids in Salvia lavandulaefolia essential oil. Pharmacol Biochem Behav 2003;75:661-668.
21. Eidi M, Eidi A, Bahar M. Effects of Salvia officinalis L. (sage) leaves on memory retention and its interaction with the cholinergic system in rats. Nutrition 2006;22:321-326.
22. Perry NS, Houghton PJ, Theobald A, Jenner P, Perry EK. In vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol 2000;52:895-902.
23. Perry N, Houghton P, Jenner P, Keith A, Perry E. Salvia lavandulaefolia essential oil inhibits cholinesterase in vivo. Phytomedicine 2002;9:48-51.
24. Kennedy DO, Pace S, Haskell C, Okello EJ, Milne A, Scholey AB. Effects of cholinesterase inhibiting sage (Salvia officinalis) on mood, anxiety and performance on a psychological stressor battery. Neuropsychopharmacology 2006;31:845-852.
25. Kennedy DO, Dodd FL, Robertson BC, et al. Monoterpenoid extract of sage (Salvia lavandulaefolia) with cholinesterase inhibiting properties improves cognitive performance and mood in healthy adults. J Psychopharmacol 2010;25:1088-1100.
26. Moss L, Rouse M, Wesnes KA, Moss M. Differential effects of the aromas of Salvia species on memory and mood. Hum Psychopharmacol 2010;25:388-396.
27. Akhondzadeh S, Noroozian M, Mohammadi M, et al. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double blind, randomized and placebo, controlled trial. J Clin Pharm Ther 2003;28:53-59.
28. Mayer E, Gescheidt-Shoshany H, Weltfriend S. Allergic contact dermatitis caused by Salvia officinalis extract. Contact Derm 2011; 64:237-238.
29. Halicioglu O, Astarcioglu G, Yaprak I, Aydinlioglu H. Toxicity of Salvia officinalis in a newborn and a child: An alarming report. Pediatr Neurol 2011;45:259-260.
30. Schulz KF, Grimes DA. Blinding in randomised trials: Hiding who got what. Lancet 2002;359:696-700.
31. Karanicolas PJ, Farrokhyar F, Bhandari M. Blinding: Who, what, when, why, how? Can J Surg 2010;53:345.
32. Miller KD, Rahman ZU, Sledge GW Jr. Selection bias in clinical trials. Breast Dis 2001;14:31-40.
33. Viera AJ, Bangdiwala SI. Eliminating bias in randomized controlled trials: Importance of allocation concealment and masking. Fam Med 2007;39:132.
34. Council PoHMDiCTNR. The prevention and treatment of missing data in clinical trials. Panel on handling missing data in clinical trials. Committee on National Statistics, Division of Behavioral and Social Sciences and Education. Washington, DC: The National Academies Press, 2010.
35. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012;367:1355-1360.
36. Huwiler-Müntener KJP, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. JAMA 2002;287:2801-2804.
37. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
38. Bond A, Lader M. The use of analog scales in rating subjective feelings. Br J Med Psychol 1974;47:211-218.
39. Simpson PM, Surmon D, Wesnes KA, Wilcock G. The cognitive drug research computerized assessment system for demented patients: A validation study. Int Psychogeriatr 1991;6:95-102.
40. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
41. Kennedy DO, Scholey AB. A glucose-caffeine, energy drink, ameliorates subjective and performance deficits during prolonged cognitive demand. Appetite 2004;42:331-333.
42. Brain, Performance and Nutrition Research Centre. Compass Cognitive System (2013). http://www.cognitivetesting.co.uk.
43. Wetherell MA, Sidgreaves MC. Secretory immunoglobulin-A reactivity following increases in workload intensity using the Defined Intensity Stressor Simulation (DISS). Stress Health 2002;21:99-106.
44. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
45. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric inventory comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308.
46. Spielberger CD. State-trait anxiety inventory. The Corsini encyclopedia of psychology. New York, NY: John Wiley & Sons Inc., 2010.